ISC10 Antibody

What is Isc10 and why are antibodies against it important for research?

Isc10 is a meiosis-specific inhibitory protein that forms complexes with Smk1 (a Mitogen-Activated Protein Kinase) during meiosis I. It plays a critical role in cell cycle regulation, specifically in the coupling of spore differentiation to the G0-like phase of the cell cycle. Isc10 forms an inhibited complex with Smk1 during meiosis I and later forms a ternary complex with Ssp2 and Smk1 during meiosis II that is poised for activation .

Antibodies against Isc10 are essential research tools that allow scientists to:

• Track Isc10 protein expression and localization during meiosis

• Study temporal dynamics of Isc10-Smk1-Ssp2 complex formation

• Investigate post-translational modifications of Isc10, including ubiquitylation

• Examine protein-protein interactions in different genetic backgrounds

These applications provide crucial insights into cell cycle regulation mechanisms and meiotic progression, which have broad implications for understanding fertility and reproductive biology.

How is Isc10 expression regulated during meiosis?

Isc10 exhibits a distinct temporal expression pattern during meiosis. Research shows that Isc10 is undetectable in vegetative cultures but accumulates in parallel with Smk1 starting around 5 hours post-induction of meiosis, reaching maximum concentration at approximately 6.5 hours. Unlike Smk1, which persists longer, Isc10 levels decrease substantially between 6.5 and 8 hours post-induction, coinciding with the completion of meiosis II .

This degradation pattern is APC/C^Ama1-dependent, as demonstrated by studies showing that in ama1Δ and swm1Δ mutants, the reduction in Isc10 levels does not occur. Additionally, experiments with the proteasome inhibitor MG132 have revealed that Isc10 is polyubiquitylated in a pathway requiring APC/C^Ama1 . Antibodies specific to Isc10 are essential for monitoring these temporal dynamics and regulatory mechanisms.

What are the optimal experimental conditions for detecting Isc10 ubiquitylation using antibodies?

Detecting Isc10 ubiquitylation requires careful experimental design. Based on published protocols, researchers should consider the following methodological approach:

• Timing of sample collection: Collect samples as meiosis I is being completed (approximately 5.5 hours post-induction) and at intervals afterward to capture the ubiquitylation dynamics .

• Proteasome inhibition: Treat cells with a proteasome inhibitor such as MG132 to prevent degradation of ubiquitylated proteins. This step is critical for visualizing the polyubiquitylation ladder of Isc10 .

• Protein tagging strategy: Utilize a dual-tag approach, such as the Isc10-HBH system, which allows for purification under denaturing conditions to maintain ubiquitin attachments. Purify using nickel beads or other appropriate methods based on the tag employed .

• Detection antibodies: Use anti-ubiquitin antibodies in conjunction with anti-Isc10 antibodies to confirm ubiquitylation specifically on Isc10 rather than associated proteins.

• Controls: Include ama1Δ samples as negative controls, as these show reduced high-molecular-weight ubiquitin immunoreactivity compared to wild-type samples .

This methodology allows for reliable detection of the transient ubiquitylation states of Isc10 that occur during the meiotic progression.

How can researchers distinguish between free Isc10 and Isc10 bound in protein complexes using antibody-based techniques?

Distinguishing between free Isc10 and Isc10 bound in complexes with Smk1 and/or Ssp2 requires sophisticated antibody-based techniques:

• Co-immunoprecipitation (Co-IP): Use anti-Isc10 antibodies to pull down Isc10 and associated proteins. Western blotting with antibodies against Smk1 and Ssp2 can then reveal complex formation. Research has shown that Isc10 forms different complexes at different stages of meiosis - a binary complex with Smk1 during MI and a ternary complex with Smk1 and Ssp2 during MII .

• Size-exclusion chromatography combined with immunoblotting: This approach separates protein complexes based on size, followed by antibody detection of Isc10, Smk1, and Ssp2 in the fractions to determine which proteins co-migrate in complexes.

• Blue native PAGE: This technique preserves protein-protein interactions during electrophoresis and can be combined with antibody detection to identify native complexes containing Isc10.

• Proximity ligation assay (PLA): This in situ technique can detect protein-protein interactions in fixed cells using pairs of antibodies against Isc10 and its binding partners (Smk1, Ssp2).

• FRET-based approaches: Using fluorescently-labeled antibodies or expression of fluorescently-tagged proteins to detect energy transfer between closely associated proteins.

These approaches provide complementary information about the dynamics of Isc10 complexes during meiotic progression.

How should researchers interpret contradictory results between Isc10 antibody detection and genetic knockout studies?

When faced with contradictory results between antibody-based detection of Isc10 and genetic knockout (isc10Δ) phenotypes, researchers should systematically evaluate several factors:

• Antibody specificity: Validate antibody specificity using isc10Δ samples as negative controls. Cross-reactivity with related proteins could lead to false-positive signals even in knockout strains .

• Functional redundancy: Consider whether other proteins compensate for Isc10 function in isc10Δ mutants. Research has shown that mutations in Isc10 alone modestly reduced spore differentiation efficiency, but when combined with mutations affecting Ssp2 timing, spores were nearly absent . This suggests potential compensatory mechanisms.

• Context-dependent effects: Analyze whether the observed contradictions are specific to certain genetic backgrounds or experimental conditions. For example, the effects of Isc10 deletion might differ between wild-type and ama1Δ backgrounds .

• Protein domain functionality: Utilize antibodies targeting different epitopes of Isc10 to determine if truncated or alternatively spliced forms of the protein retain partial functionality in apparent knockout strains. Studies have examined N- and C-terminal deletions in Isc10 to understand domain functions .

• Quantitative analysis: Apply quantitative methods like Western blotting with standard curves to determine if residual low levels of Isc10 expression remain in knockdown systems that might explain partial functionality.

A methodical evaluation of these factors will help reconcile apparently contradictory results and lead to a more comprehensive understanding of Isc10 function.

What are the considerations for analyzing Isc10 antibody reactivity in immunocompromised research models?

Analyzing Isc10 antibody reactivity in immunocompromised research models requires attention to several critical factors:

• Altered antibody kinetics: Immunocompromised models often exhibit impaired antibody production and altered kinetics. Studies with immunocompromised patients showed they were 0.61 times as likely to have infection-induced antibodies during the 14-90 days following infection compared to immunocompetent individuals .

• Stratification by immunocompromised condition type: Different types of immunocompromising conditions affect antibody responses differently. Research has shown distinct patterns for solid malignancies versus other intrinsic immune conditions . When studying Isc10 in such models, separate analyses should be conducted for different types of immunocompromising conditions.

• Temporal considerations: Immunocompromised models may show delayed antibody responses. Analysis should include multiple time points (14-90, 91-180, 181-365, and 365+ days) to capture potential delayed responses or differences in antibody persistence .

• Control selection: Properly matched controls are essential. Consider age, sex, and other demographic factors that might influence antibody responses independent of immunocompromised status .

• Statistical approach: Use longitudinal, multivariate analyses that can adjust for confounding variables. Logistic regression models that produce adjusted odds ratios comparing antibody prevalence between specimens with and without immunocompromising conditions have been successfully employed .

These considerations ensure robust analysis of Isc10 antibody reactivity in complex immunocompromised research models.

What are the best methods for expressing and purifying recombinant Isc10 for antibody production?

The optimal approach for expressing and purifying recombinant Isc10 for antibody production involves:

• Expression system selection: BL-21 DE3 Escherichia coli cells have been successfully used for Isc10 expression. For eukaryotic post-translational modifications, consider yeast or baculovirus-insect cell systems .

• Fusion tag strategy: MBP (Maltose-Binding Protein) fusion has proven effective for Isc10 expression (MBP-Isc10), enhancing solubility and facilitating purification. Alternatively, HBH-tagging (His6-Biotinylation sequence-His6) can be employed for tandem purification under denaturing conditions .

• Co-expression considerations: When studying Isc10's function, co-expression with interaction partners (Smk1, Cak1, Ssp2) may be necessary. Plasmid systems allowing simultaneous expression of multiple proteins should be employed .

• Domain-specific constructs: For challenging full-length expressions, consider expressing functional domains. Research has successfully used N- or C-terminal deletion constructs of Isc10 generated by PCR and inserted into expression plasmids .

• Verification methods: Sequence verification of all constructs is essential. Site-directed mutagenesis can be employed to modify specific residues of interest (e.g., S97, Y93, P95) for structure-function studies .

This methodological approach maximizes the likelihood of obtaining high-quality Isc10 protein for subsequent antibody development.

How can researchers optimize immunoprecipitation protocols for studying Isc10 complexes?

Optimizing immunoprecipitation (IP) protocols for studying Isc10 complexes requires attention to several critical parameters:

• Cell lysis conditions: Use conditions that preserve Isc10 complexes while efficiently extracting proteins. For meiotic cells, buffer compositions containing phosphatase inhibitors are essential to maintain phosphorylation states of complex components like Smk1 .

• Timing of sample collection: Collect samples at specific timepoints that capture the dynamic nature of Isc10 complexes. For binary Isc10-Smk1 complexes, target ~5 hours post-induction; for ternary Isc10-Smk1-Ssp2 complexes, target ~6.5 hours post-induction .

• Antibody selection and validation: For co-IP experiments, use antibodies against different epitopes of Isc10 to ensure the interaction interface is not masked. Validate antibody specificity using isc10Δ controls .

• Cross-linking strategies: Consider using mild cross-linking agents like formaldehyde or DSP (dithiobis[succinimidyl propionate]) to stabilize transient interactions, particularly for the ternary complexes formed during MII.

• Sequential immunoprecipitation: For complex purification, perform sequential IPs (first with anti-Isc10, then with anti-Smk1 or anti-Ssp2) to ensure specificity of the isolated complexes.

• Controls for ubiquitylation studies: When studying Isc10 ubiquitylation, include proteasome inhibitors (MG132) and compare wild-type samples with ama1Δ samples, which show reduced ubiquitylation of Isc10 .

Implementation of these optimized IP protocols will facilitate detailed characterization of the composition, stoichiometry, and dynamics of Isc10-containing protein complexes.

How might phospho-specific Isc10 antibodies advance our understanding of meiotic regulation?

Phospho-specific antibodies against Isc10 would significantly advance meiotic regulation research in several ways:

• Temporal phosphorylation dynamics: Phospho-specific antibodies would enable tracking of specific phosphorylation events on Isc10 during meiotic progression, providing insights into the timing of regulatory events. This is particularly relevant given the dynamic nature of Isc10's involvement in both meiosis I and II .

• Kinase-substrate relationships: These antibodies could help identify which kinases are responsible for Isc10 phosphorylation. Research has already established relationships between Smk1 (a MAPK) and Isc10, but the complete kinase network regulating Isc10 remains to be elucidated .

• Phosphorylation-dependent complex formation: Phospho-specific antibodies could determine whether specific phosphorylation states of Isc10 correlate with its ability to form complexes with Smk1 alone or with both Smk1 and Ssp2, clarifying the molecular mechanism of complex assembly and disassembly .

• Structure-function relationships: By correlating specific phosphorylation states with functional outcomes, researchers could determine how phosphorylation affects Isc10's inhibitory activity. Studies have already investigated mutations of specific residues (S97, Y93, P95) that might be phosphorylation sites .

• Integration with ubiquitylation pathway: Phospho-specific antibodies could reveal potential crosstalk between phosphorylation and ubiquitylation of Isc10, potentially uncovering how phosphorylation might prime Isc10 for APC/C^Ama1-dependent ubiquitylation and subsequent degradation .

This approach would provide a more comprehensive picture of the post-translational modification landscape regulating Isc10 function during meiosis.

What are the implications of targeting Isc10 for studying meiotic disorders?

Targeting Isc10 with specific antibodies and other molecular tools has significant implications for studying meiotic disorders:

• Biomarker development: Isc10 antibodies could be developed as biomarkers for proper meiotic progression. Since Isc10 shows a precise temporal expression pattern and degradation timing, aberrations in this pattern might indicate meiotic dysfunction .

• Mechanistic insights into infertility: Research has shown that isc10Δ mutations combined with alterations in Ssp2 timing severely impair spore formation . This suggests that Isc10 dysfunction might contribute to certain forms of infertility by disrupting the coordination between cell cycle progression and gamete differentiation.

• Model system advantages: The well-characterized role of Isc10 in yeast meiosis provides an excellent model system for studying conserved aspects of meiotic regulation. While direct orthologs might not exist in all species, the regulatory principles could be conserved through functional homologs.

• Therapeutic target evaluation: Understanding Isc10's role in inhibiting Smk1 MAPK could inform approaches to modulating MAPK pathways therapeutically in reproductive contexts. The bacterial expression systems and in vitro biochemical reactions established for studying Isc10-Smk1 interactions provide platforms for screening potential modulators .

• Integration with clinical research: Combining basic research on Isc10 with clinical studies of meiotic disorders could identify correlations between specific molecular defects and clinical presentations, potentially leading to more precise diagnostic and therapeutic approaches.

This research direction highlights the translational potential of fundamental studies on meiotic regulators like Isc10.